Eli Lilly is working to cut 200 R&D positions. The Big Pharma is framing the action as a “voluntary reallocation program” that will see it reduce its global R&D headcount by nearly 3% while it ups its investment in other areas.
The cuts, news of which was first reported by Stat, follow shortly after Lilly detailed plans to ax 485 employees in response to the failure of its Alzheimer’s trial. But, according to the company, the aim this time is different. Lilly is looking for 200 staffers from multiple R&D sites around the world to voluntarily sign up to leave the company.
While the earlier, larger cuts followed the fading of expectations for solanezumab and subsequent retreat from the program, the latest action is being pitched as a tweaking of the Lilly R&D machine ahead of renewed investment in specific areas of the operation.
“Lilly is focusing its investment in new R&D capabilities to ensure portfolio sustainability. We plan to increase our investment and hire in strategic areas, including molecule-making capabilities, immunology and Alzheimer’s disease, across our U.S. research sites later this year,” a spokesperson who confirmed the cuts said in an emailed statement.
The reference to U.S. research sites is notable given the political climate in which Lilly is operating. News of the cuts emerged days after Lilly CEO Dave Ricks talked up his hiring of manufacturing staff in a meeting with President Donald Trump. Given Trump’s willingness to single out firms for criticism on Twitter and uncertainty over his approach to biopharma, there is value in being seen to be on board with the “America First” approach, particularly as it relates to jobs.
Lilly’s statement also suggests the company is pushing ahead in Alzheimer’s despite the setbacks it has faced. Jobs related to Alzheimer’s research are among the 34 open science positions at Lilly as of today. Lilly is also looking to add a team leader at its neuroscience R&D unit in the U.K.
By Nick Paul Taylor
Source: Fierce Biotech
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.